Gregory Cote is a Gastroenterology physician. ClinicalTrials.gov lists 11 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3303 S Bond Ave
Portland, OR 972394501
Telephone
503-494-4373Provider last certified this registry record 7 Sept 2021.
Clinical trials
- Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
Sponsor: National Cancer Institute (NCI)
- Lurbinectedin + Doxorubicin In Leiomyosarcoma
Sponsor: Massachusetts General Hospital
- Pancreatic Endotherapy for Refractory Chronic Pancreatitis
Sponsor: Oregon Health and Science University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boston Scientific CorporationProgram year20253 payments
- Boston Scientific CorporationProgram year20245 payments
- Olympus CorporationProgram year202316 payments$10,602openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Antidiarrheal microorganisms58.9%Creon67%Zenpep33%Part D<11 patientsProton pump inhibitor29.5%Omeprazole61%Esomeprazole Magnesium39%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs
Oregon Health & Science University
FY2026$766,920U01CA278923 - Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs
Oregon Health & Science University
FY2025$766,920U01CA278923 - Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs
Oregon Health & Science University
FY2024$728,573U01CA278923
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Josep M. Llovet
Institució Catalana de Recerca i Estudis Avançats
Joseph J.�Y. Sung
Nanyang Technological University
Neeraj Bhala
The Royal Melbourne Hospital
Jordi Bruix
Hospital Clínic de Barcelona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”